Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Of note, collaboration of GAB2 with mutant NRAS enhanced tumorigenesis in vivo and led to an increased vessel density with strong CD34 and VEGFR2 activity.
|
22926523 |
2013 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We also observed that DKK-3 suppresses endothelial cell angiogenesis of β2M through vascular endothelial growth factor receptor-2 (VEGFR-2) in tumorigenesis.
|
26278164 |
2015 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
JZC01 targeted vascular endothelial growth factor receptor 2 (VEGFR2) and inhibited tumorigenesis by blocking the VEGFR2 signaling pathway.
|
31428800 |
2019 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Gremlin 1 (GREM1), as a bone morphogenetic protein (BMP) antagonist and vascular endothelial growth factor receptor-2 (VEGFR2) novel agonist, has been confirmed as overexpressed in colorectal cancer (CRC) tissues but its role in carcinogenesis remains unclear.
|
30426548 |
2019 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This protein has characteristics of a tyrosine kinase growth factor receptor and is postulated to be important in human carcinogenesis.
|
1974168 |
1990 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
NRP1 and VEGFR2 might play a role in colon carcinogenesis and development of metastases.
|
19360289 |
2009 |
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Within this family of receptors, VEGFR 2/kinase-insert-domain containing receptor appears to be principally upregulated during tumorigenesis.
|
23273598 |
2013 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Kinase insert domain receptor (KDR) is the principal receptor that promotes the proangiogenic action of vascular endothelial growth factor and is involved in the tumorigenesis and progression of many malignancies, including hepatocellular carcinoma (HCC).
|
25123269 |
2014 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our preclinical work indicates that anlotinib acts as a novel inhibitor of VEGFR2 and MET that blocks tumorigenesis in osteosarcoma, which could be translated into future clinical trials.
|
30719715 |
2019 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
VEGFR1 and VEGFR2 in lip carcinogenesis and its association with microvessel density.
|
25895461 |
2015 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
It drives tumorigenesis by activating downstream hypoxia responsive genes and proangiogenic factors like VEGFR, and is responsible for the activity of tyrosine kinase inhibitors in RCC.
|
31184937 |
2019 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In this study, we evaluated whether the anti-VEGFR monoclonal antibody (Mab) DC101 in combination with paclitaxel inhibited tumorigenesis, angiogenesis, and metastasis of human TCC growing within the bladder of athymic nude mice.
|
10914704 |
2000 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
VEGFR2 Signaling Prevents Colorectal Cancer Cell Senescence to Promote Tumorigenesis in Mice With Colitis.
|
25797700 |
2015 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MARCKSL1 disrupted phosphorylation of vascular endothelial growth factor receptor-2 (VEGFR-2) in ovarian tumorigenesis.
|
26555156 |
2016 |
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Similarly, Flk-1 expression was also found in some thyroid tumors, while the expression of c-Kit-mediated pathways may not play a major role in thyroid tumorigenesis.
|
16570574 |
2006 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This study contributes to breast cancer prognosis and therapeutic design by providing genetic evidence of interactions between ANLN and KDR, and suggesting the prominent role of the immune response in driving the synergies between the cancer cell life/death and angiogenesis/metastasis transitions during carcinogenesis.
|
31578580 |
2019 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer.
|
30819137 |
2019 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Surface PD-L1, E-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis.
|
28851898 |
2017 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Prompted by the hypothesis that VEGF/Flk-1 system may have regulatory roles in breast carcinogenesis, we investigated the expression of Flk-1 in 141 invasive breast carcinomas in correlation with clinical and immunohistochemical prognostic parameters, including proliferation indices like Ki-67 and Topoisomerase IIalpha (Topo-IIalpha).
|
12378509 |
2002 |
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Of note, Gab2 enhanced tumorigenesis and tumor growth in mouse xenografts with high Ki67 expression, and led to an increased vessel density with strong CD34 and VEGFR2 activity.
|
28420432 |
2017 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
It promotes tumorigenesis via formation of the NRP-1/ VEGF (vascular endothelial growth factor)/VEGFR2 (vascular endothelial growth factor receptor 2) complex.
|
26916409 |
2016 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Vascular endothelial growth factor receptor 2 (VEGFR2) and c‑Met are tyrosine kinases, which are involved in the tumorigenesis of various types of cancer.
|
30015973 |
2018 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Moreover, we identified four novel candidate cancer-associated genes (CTCF, ARHGAP35, NF1, and KDR) which may be crucial in the carcinogenesis of EEC.
|
30886832 |
2019 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
VEGF, FLT-1 and FLK-1 are associated with colorectal carcinogenesis. siRNA silencing of the VEGF gene suppresses proliferation, and induces apoptosis in HCT116 cells.
|
20205278 |
2010 |